Sarepta Eyes Patient Outcomes To Boost Exondys 51's European Review
EMA and payers want to know more about daily life improvements from US FDA-approved Duchenne muscular dystrophy treatment.
EMA and payers want to know more about daily life improvements from US FDA-approved Duchenne muscular dystrophy treatment.